These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 20427496)

  • 1. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
    Rasmussen MH; Bysted BV; Anderson TW; Klitgaard T; Madsen J
    J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
    Søndergaard E; Klose M; Hansen M; Hansen BS; Andersen M; Feldt-Rasmussen U; Laursen T; Rasmussen MH; Christiansen JS
    J Clin Endocrinol Metab; 2011 Mar; 96(3):681-8. PubMed ID: 21177789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile.
    Rasmussen MH; Jensen L; Anderson TW; Klitgaard T; Madsen J
    Clin Endocrinol (Oxf); 2010 Dec; 73(6):769-76. PubMed ID: 20718773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
    Rasmussen MH; Olsen MW; Alifrangis L; Klim S; Suntum M
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1819-29. PubMed ID: 25013997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics.
    de Schepper J; Rasmussen MH; Gucev Z; Eliakim A; Battelino T
    Eur J Endocrinol; 2011 Sep; 165(3):401-9. PubMed ID: 21724838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
    Rasmussen MH; Janukonyté J; Klose M; Marina D; Tanvig M; Nielsen LF; Höybye C; Andersen M; Feldt-Rasmussen U; Christiansen JS
    J Clin Endocrinol Metab; 2016 Mar; 101(3):988-98. PubMed ID: 26727076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A long-acting pegylated recombinant human growth hormone (Jintrolong
    Guan Y; He F; Wu J; Zhao L; Wang X; Huang L; Zeng G; Ren B; Chen J; Liao X; Ma Z; Chen X; Zhong G; Huang M; Zhao X
    J Clin Pharm Ther; 2018 Oct; 43(5):640-646. PubMed ID: 29959799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
    Kemp SF; Fielder PJ; Attie KM; Blethen SL; Reiter EO; Ford KM; Marian M; Dao LN; Lee HJ; Saenger P
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3234-40. PubMed ID: 15240597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of GH: dependence on route and dosage of administration.
    Keller A; Wu Z; Kratzsch J; Keller E; Blum WF; Kniess A; Preiss R; Teichert J; Strasburger CJ; Bidlingmaier M
    Eur J Endocrinol; 2007 Jun; 156(6):647-53. PubMed ID: 17535864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L; Chen ZH; Liu D; Cheng YG; Luo XP
    Drug Des Devel Ther; 2016; 10():13-21. PubMed ID: 26719670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
    Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile.
    Jostel A; Mukherjee A; Alenfall J; Smethurst L; Shalet SM
    Clin Endocrinol (Oxf); 2005 May; 62(5):623-7. PubMed ID: 15853836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency.
    Biller BM; Ji HJ; Ahn H; Savoy C; Siepl EC; Popovic V; Coculescu M; Roemmler J; Gavrila C; Cook DM; Strasburger CJ
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1718-26. PubMed ID: 21411551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety.
    Walvoord EC; de la Peña A; Park S; Silverman B; Cuttler L; Rose SR; Cutler G; Drop S; Chipman JJ
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2052-9. PubMed ID: 19336514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
    Teichman SL; Neale A; Lawrence B; Gagnon C; Castaigne JP; Frohman LA
    J Clin Endocrinol Metab; 2006 Mar; 91(3):799-805. PubMed ID: 16352683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in growth hormone response to exercise before and after rhGH administration and the effect of rhGH on the hormone profile of fit normal adults.
    Giannoulis MG; Boroujerdi MA; Powrie J; Dall R; Napoli R; Ehrnborg C; Pentecost C; Cittadini A; Jørgensen JO; Sonksen PH;
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):315-22. PubMed ID: 15730413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.
    Cook DM; Biller BM; Vance ML; Hoffman AR; Phillips LS; Ford KM; Benziger DP; Illeperuma A; Blethen SL; Attie KM; Dao LN; Reimann JD; Fielder PJ
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4508-14. PubMed ID: 12364427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.